A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report.
Cho D, Heath E, Cleary J, Kwak E, Gandhi L, Lawrence D, Zack C, Teofilovici F, Bradley R, Karol M, Shapiro G, LoRusso P. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. Journal Of Clinical Oncology 2011, 29: 3051-3051. DOI: 10.1200/jco.2011.29.15_suppl.3051.Peer-Reviewed Original ResearchPhase I dose-escalation studyI dose-escalation studyDose-escalation studyHSP90 inhibitor ganetespibSolid tumors